CarolynDoloresBrittenMD

Oncology • Charleston, SC

Gastrointestinal Cancer, Hematologic Oncology

Director, Division of Hematology/Oncology Associate Professor at Medical University of South Carolina

Join to view full profile

Dr. Britten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Britten's full profile

Already have an account?

Office
86 Jonathan Lucas St
Charleston, SC 29425
Phone+1 843-792-9300

Fax+1 843-792-1190
Is this information wrong?

Education & Training

University of Toronto Faculty of MedicineClass of 1992

Certifications & Licensure

SC State Medical License 2012 - 2025
CA State Medical License 2001 - 2024
TX State Medical License 1997 - 2009
American Board of Internal Medicine Medical Oncology
Royal College of Physicians and Surgeons of CanadaInternal Medicine
Royal College of Physicians and Surgeons of CanadaMedical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression Start of enrollment: 2001 Aug 01
Completed
Phase 1, Phase 2
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction Start of enrollment: 2002 May 01
Completed
Phase 1
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery Start of enrollment: 2003 Jun 01
Completed
Phase 2
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Dec 01
Completed
Phase 1
CP-724,714 in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 1
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2005 Oct 01
Unknown status
Phase 1
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Start of enrollment: 2013 Aug 01
Terminated
Phase 1
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2019 Sep 30
Withdrawn
Phase 2
AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy Start of enrollment: 2017 Jun 06
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Christian Kollmannsberger, Carolyn D. Britten, Anthony J. Olszanski, Joan Andrews Walker, Wei Zang, Melinda D. Willard, David B. Radtke, Daphne L. Farrington, Katherin...> ;Investigational New Drugs. 2021 Jul 15
2 citations
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Darcy B. Pooler, Dylan B. Ness, John Sarantopoulos, Nicholas Squittieri, Shoba Ravichandran, Carolyn D. Britten, Ravi K. Amaravadi, Ulka N. Vaishampayan, Patricia LoRu...> ;British Journal of Clinical Pharmacology. 2021 Mar 1
90 citations
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line trea...
Marcus Smith Noel, Eileen M. O'Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, Eric C Gamelin, Bishu J ...> ;Investigational New Drugs. 2020 Jun 1
28 citations
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
Antonio Giordano, Y Liu, Kent Armeson, Yeonhee Park, Maya Ridinger, Mark G. Erlander, James M. Reuben, Carolyn D. Britten, Christiana S. Kappler, Elizabeth S. Yeh, Ste...> ;Plos One. 2019 Nov 21
25 citations
Automatic trial eligibility surveillance based on unstructured clinical data
Stéphane M. Meystre, Paul M. Heider, Youngjun Kim, Daniel B. Aruch, Carolyn D. Britten> ;International Journal of Medical Informatics. 2019 Sep 1
408 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun Wook Lee, Mathew Taylor, ...> ;The Lancet. Oncology. 2018 Jan 1
57 citations
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg, Maria Alsina, Heloisa P. Soares, Irene Brana, Carolyn D. Britten, Gianluca Del Conte, Patrick Ezeh, Brett E. Houk, Kenneth A. Kern, Stephen Leong, Nuz...> ;Targeted Oncology. 2017 Oct 24
24 citations
Racial Differences in Stage IV Colorectal Cancer Survival in Younger and Older Patients
Kristin Wallace, Allan DeToma, David N. Lewin, Shaoli Sun, Don C. Rockey, Carolyn D. Britten, Jennifer D. Wu, Aissatou Ba, Anthony J. Alberg, Elizabeth G. Hill> ;Clinical Colorectal Cancer. 2017 Sep 1
107 citations
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
Carolyn D. Britten, Elizabeth Garrett-Mayer, Steven H. Chin, Keisuke Shirai, Besim Ogretmen, Tricia A. Bentz, Alan Brisendine, Kate Anderton, Susan L. Cusack, Lynn W. ...> ;Clinical Cancer Research. 2017 Aug 15
21 citations
Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients
Antoinette S. Gomes, P. Monteleone, James Sayre, Richard S. Finn, Saeed Sadeghi, Myron J. Tong, Carolyn D. Britten, Ronald W. Busuttil> ;AJR. American Journal of Roentgenology. 2017 Jul 13
100 citations
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. T...> ;Journal of Hematology & Oncology. 2017 Apr 7
17 citations
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and ce...
Jennifer R. Diamond, Barbara A. Goff, Martin D. Forster, Johanna C. Bendell, Carolyn D. Britten, Michael S. Gordon, Hani Gabra, David M. Waterhouse, Mark Poole, D. Ros...> ;Investigational New Drugs. 2017 Mar 10
12 citations
Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.
Yefim Manevich, Leticia Reyes, Carolyn D. Britten, Danyelle M. Townsend, Kenneth D. Tew> ;The Journal of Pharmacology and Experimental Therapeutics. 2016 Aug 1
224 citations
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients w...
Philippe L. Bedard, Josep Tabernero, Filip Janku, Zev A. Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, Jose Perez-Garcia, Anastasios Stathis, Carolyn ...> ;Clinical Cancer Research. 2015 Feb 15
5 citations
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D. Britten, Joanne E. Mortimer, Swarupa Kulkarni, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, Daniel J. George> ;Cancer Chemotherapy and Pharmacology. 2014 Sep 6
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Britten, C. D.,Adjei, A. A.,Millham, R.,Houk, B. E.,Borzillo, G.,Pierce, K.,Wainberg, Z. A.,Lorusso, P. M.> ;Invest New Drugs. 2014 Feb 18
16 citations
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
Margaret von Mehren, Carolyn D. Britten, Peter C Pieslor, Wayne Saville, Artemios Vassos, Sarah Harris, Gerald R. Galluppi, Mohamed Darif, Zev A. Wainberg, Roger B. Co...> ;Investigational New Drugs. 2014 Jan 24
81 citations
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Edward B. Garon, Heather R. Christofk, Wylie Hosmer, Carolyn D. Britten, Agnes Bahng, Matthew J. Crabtree, Candice Sun Hong, Naeimeh Kamranpour, Sharon Pitts, Fairooz ...> ;Journal of Cancer Research and Clinical Oncology. 2014 Jan 18
55 citations
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen J. Pierce, Zev A. Wainberg, Patricia LoRusso> ;Investigational New Drugs. 2014 Jan 7
119 citations
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, Karen S. Jacks, Monica M. Mita, Vassiliki A. Papadimitrakopoulou, Tim Pluard, Thomas A. Samu...> ;Clinical Cancer Research. 2013 Jul 1
31 citations
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignanc...
Monica M. Mita, E. Poplin, Carolyn D. Britten, William D. Tap, Eric H. Rubin, B. B. Scott, Lori Berk, Victor M. Rivera, John W. Loewy, Pierre F. Dodion, Frank G. Halus...> ;Annals of Oncology. 2013 Apr 1
164 citations
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Carolyn D. Britten> ;Cancer Chemotherapy and Pharmacology. 2013 Feb 27
55 citations
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Denni...> ;Molecular Cancer Therapeutics. 2012 Sep 1
37 citations
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study
Carolyn D. Britten, Antoinette S. Gomes, Zev A. Wainberg, David Elashoff, Rafael G. Amado, Yan Xin, Ronald W. Busuttil, Dennis J. Slamon, Richard S. Finn> ;BMC Cancer. 2012 Jan 14
Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
Bottino D, Tabernero J, Burris HA, Britten C, Chen LC, Bendell JC, Chiparus O, Duval V, Di Tomaso E, Sarr C, Hackl W, Baselga J, Rodon Ahnert J> ;J. Clin. Oncol.. 2011-05-20
Join now to see all

Professional Memberships

Hospital Affiliations

MUSC Health University Medical CenterCharleston, South Carolina
Roper HospitalCharleston, South Carolina